Schertenleib
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
Schertenleib stands out as exclusively dedicated to patent litigation with noteworthy strength in the life sciences and pharmaceuticals industries. The practice excels in high-stakes disputes, regulatory counsel and multi-jurisdictional matters and is headed by founder Denis Schertenleib, a physicist with a PhD in molecular neurobiology focusing on patent litigation, arbitration and pharma regulatory matters. Ombeline Degèze-Péchade is renowned for innovative patent and regulatory strategies, and Marc Lauzeral is a name to note for cross-border patent and SPC disputes.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘A multidisciplinary team providing precise and efficient service tailored to each situation. No topics are off-limits in discussions; they take all of their clients' concerns into account.’
- ‘The Schertenleib team comprises highly skilled lawyers known for their sharp analytical minds and extensive patent litigiation experience, in particular in the pharmaceutical and life sciences sectors. Their profound understanding of the technical and scientific background enables them to deliver comprehensive legal analysis and advice that meticulously considers all relevant aspects. They are diligent, deeply committed, exceptionally knowledgeable, and consistently responsive.’
Key clients
- Recor Medical Inc. & Otsuka Medical Device
- Viatris
Work highlights
Represented Sandoz successfully in invalidity proceedings against Bayer’s patent relating to Rivaroxaban (marketed as Xarelto), one of Bayer’s blockbuster drugs and a strategic product for the client’s European portfolio.